J&J picks up pace for Warp Speed COVID-19 vaccine

One Operation Warp Speed finalist is advancing its COVID-19 vaccine into the clinic two months earlier than planned as the U.S. initiative looks to a 170-year-old company to produce glass packaging for countermeasures. Meanwhile, a new joint venture based in Ireland is developing its own vaccine and has an eye on global access.

Johnson & Johnson (NYSE:JNJ) announced Wednesday plans to begin in the second half of July human trials of its adenoviral vector COVID-19 vaccine: Ad26.COV2-S, recombinant. The Phase I/IIa study in the U.S. and Belgium will enroll individuals ages 18-55 as well as adults ages 65 and older...